Rituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease

被引：43
|
作者：
Teshima, Takanori [1 ]
Nagafuji, Koji [2 ]
Henzan, Hideho [3 ]
Miyamura, Koichi [4 ]
Takase, Ken [3 ]
Hidaka, Michihiro [5 ]
Miyamoto, Toshihiro [1 ,2 ]
Takenaka, Katsuto [2 ]
Akashi, Koichi [1 ,2 ]
Harada, Mine [2 ]
机构：
[1] Kyushu Univ, Grad Sch Med Sci, Ctr Cellular & Mol Med, Higashi Ku, Fukuoka 8128582, Japan
[2] Kyushu Univ, Grad Sch Med Sci, Dept Med & Biosyst Sci, Higashi Ku, Fukuoka 8128582, Japan
[3] Hamanomachi Gen Hosp, Dept Hematol, Fukuoka, Japan
[4] Japanese Red Cross Nagoya Daiichi Hosp, Dept Hematol, Nagoya, Aichi, Japan
[5] Natl Hosp Org, Kumamoto Med Ctr, Dept Internal Med, Kumamoto, Japan
来源：
INTERNATIONAL JOURNAL OF HEMATOLOGY | 2009年 / 90卷 / 02期
关键词：
Rituximab; Chronic GVHD; Corticosteroids; Allogeneic transplantation; ANTI-CD20; MONOCLONAL-ANTIBODY; CONSENSUS DEVELOPMENT PROJECT; BONE-MARROW-TRANSPLANTATION; WORKING GROUP-REPORT; MINOR HISTOCOMPATIBILITY ANTIGEN; STEM-CELL TRANSPLANTATION; CLINICAL-TRIALS; B-CELLS; CHRONIC GVHD; THERAPY;
D O I：
10.1007/s12185-009-0370-x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
We prospectively evaluated the safety and efficacy of the anti-CD20 chimeric monoclonal antibody rituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation. Seven patients were treated with 375 mg/m(2) rituximab weekly for 4 consecutive weeks. Rituximab was well tolerated with no severe toxicity observed during treatment. At 1 year, 3 patients showed a partial response to rituximab therapy, 3 had stable disease, and 1 had progressive disease. Rituximab allowed a reduction in the dose of steroids in 4 patients. Responsive manifestations included mild to moderate skin and oral lesions, and immune hemolytic anemia, and thrombocytopenia. Severe manifestations involving the skin, fascia, and eye did not respond to treatment. These observations suggest that rituximab therapy may be effective for select patients with corticosteroid-refractory chronic GVHD that is not advanced.
引用
收藏
页码：253 / 260
页数：8
相关论文
共 50 条
  • [21] Rituximab as salvage therapy for refractory sclerodermatous chronic graft-versus-host disease
    Namdaroglu, S.
    Iskender, D.
    Dal, M. S.
    Cakar, M. K.
    Tekgunduz, E.
    Altuntas, F.
    HONG KONG JOURNAL OF DERMATOLOGY & VENEREOLOGY, 2019, 27 (01): : 12 - 18
  • [22] Evaluation of pentostatin in corticosteroid-refractory chronic graft-versus-host disease in children: a Pediatric Blood and Marrow Transplant Consortium study
    Jacobsohn, David A.
    Gilman, Andrew L.
    Rademaker, Alfred
    Browning, Brittan
    Grimley, Michael
    Lehmann, Leslie
    Nemecek, Eneida R.
    Thormann, Kimberly
    Schultz, Kirk R.
    Vogelsang, Georgia B.
    BLOOD, 2009, 114 (20) : 4354 - 4360
  • [23] Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab
    Solomon, Scott R.
    Sizemore, Connie A.
    Ridgeway, Michelle
    Zhang, Xu
    Smith, Judith
    Brown, Stacey
    Holland, H. Kent
    Morris, Lawrence E.
    Bashey, Asad
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (09) : 1576 - 1582
  • [24] Ruxolitinib: a potential treatment for corticosteroid refractory acute graft-versus-host disease
    Abedin, Sameem M.
    Hamadani, Mehdi
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (05) : 423 - 427
  • [25] Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey
    Zeiser, R.
    Burchert, A.
    Lengerke, C.
    Verbeek, M.
    Maas-Bauer, K.
    Metzelder, S. K.
    Spoerl, S.
    Ditschkowski, M.
    Ecsedi, M.
    Sockel, K.
    Ayuk, F.
    Ajib, S.
    de Fontbrune, F. S.
    Na, I-K
    Penter, L.
    Holtick, U.
    Wolf, D.
    Schuler, E.
    Meyer, E.
    Apostolova, P.
    Bertz, H.
    Marks, R.
    Luebbert, M.
    Waesch, R.
    Scheid, C.
    Stoelzel, F.
    Ordemann, R.
    Bug, G.
    Kobbe, G.
    Negrin, R.
    Brune, M.
    Spyridonidis, A.
    Schmitt-Graeff, A.
    van der Velden, W.
    Huls, G.
    Mielke, S.
    Grigoleit, G. U.
    Kuball, J.
    Flynn, R.
    Ihorst, G.
    Du, J.
    Blazar, B. R.
    Arnold, R.
    Kroeger, N.
    Passweg, J.
    Halter, J.
    Socie, G.
    Beelen, D.
    Peschel, C.
    Neubauer, A.
    LEUKEMIA, 2015, 29 (10) : 2062 - 2068
  • [26] Daclizumab for children with corticosteroid refractory graft-versus-host disease
    D T Teachey
    B Bickert
    N Bunin
    Bone Marrow Transplantation, 2006, 37 : 95 - 99
  • [27] Daclizumab for children with corticosteroid refractory graft-versus-host disease
    Teachey, DT
    Bickert, B
    Bunin, N
    BONE MARROW TRANSPLANTATION, 2006, 37 (01) : 95 - 99
  • [28] Rituximab in chronic graft-versus-host disease of the lung
    von Olshausen, I
    Spyridonidis, A
    Bremer, HC
    Windisch, W
    Bertz, H
    Finke, J
    BONE MARROW TRANSPLANTATION, 2006, 37 : S312 - S312
  • [29] Rituximab responsive refractory acute graft-versus-host disease
    Kamble, R.
    Obolendt, M.
    Carrum, G.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (11) : 1201 - 1202
  • [30] Rituximab is an effective treatment for refractory chronic graft-versus-host disease but is associated with high incidence of infections
    Batsis, I.
    Karpouza, A.
    Sakellari, I.
    Yannaki, E.
    Kaloyannidis, P.
    Mallouri, D.
    Smias, C.
    Fassas, A.
    Anagnostopoulos, A.
    Papanicolaou, G.
    BONE MARROW TRANSPLANTATION, 2009, 43 : S137 - S137
12345